Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Research Design | 29 | 2024 | 6174 | 3.490 |
Why?
|
Bayes Theorem | 21 | 2024 | 2326 | 2.900 |
Why?
|
Glioblastoma | 17 | 2023 | 3481 | 2.560 |
Why?
|
Clinical Trials as Topic | 18 | 2024 | 7995 | 1.630 |
Why?
|
Information Dissemination | 5 | 2024 | 1125 | 1.500 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2024 | 326 | 1.470 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2024 | 10199 | 1.310 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2022 | 629 | 1.100 |
Why?
|
Probability | 5 | 2023 | 2475 | 0.900 |
Why?
|
Brain Neoplasms | 13 | 2023 | 9026 | 0.890 |
Why?
|
Medical Futility | 2 | 2022 | 136 | 0.860 |
Why?
|
Data Interpretation, Statistical | 6 | 2018 | 2689 | 0.860 |
Why?
|
Maximum Tolerated Dose | 2 | 2024 | 883 | 0.830 |
Why?
|
Models, Statistical | 8 | 2024 | 5073 | 0.800 |
Why?
|
Random Allocation | 4 | 2023 | 2392 | 0.740 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2021 | 186 | 0.720 |
Why?
|
Biometry | 2 | 2014 | 561 | 0.670 |
Why?
|
Drugs, Investigational | 1 | 2021 | 212 | 0.630 |
Why?
|
Computer Simulation | 13 | 2023 | 6233 | 0.630 |
Why?
|
Medical Oncology | 4 | 2023 | 2317 | 0.600 |
Why?
|
Informed Consent | 1 | 2024 | 1007 | 0.590 |
Why?
|
Carnitine | 1 | 2018 | 252 | 0.570 |
Why?
|
Kaplan-Meier Estimate | 7 | 2021 | 6474 | 0.550 |
Why?
|
Benchmarking | 1 | 2023 | 1045 | 0.550 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 16 | 2024 | 11736 | 0.520 |
Why?
|
Inheritance Patterns | 1 | 2018 | 341 | 0.520 |
Why?
|
Antineoplastic Agents | 5 | 2024 | 13635 | 0.510 |
Why?
|
Algorithms | 12 | 2024 | 14018 | 0.510 |
Why?
|
Tuberculosis, Multidrug-Resistant | 3 | 2021 | 934 | 0.490 |
Why?
|
Antitubercular Agents | 4 | 2021 | 1374 | 0.480 |
Why?
|
Multiple Myeloma | 9 | 2023 | 5146 | 0.470 |
Why?
|
Immunotherapy | 4 | 2022 | 4642 | 0.460 |
Why?
|
Neoplasms | 8 | 2024 | 22131 | 0.450 |
Why?
|
Survival Analysis | 6 | 2021 | 10073 | 0.440 |
Why?
|
Neurology | 1 | 2021 | 780 | 0.440 |
Why?
|
Breast Neoplasms | 15 | 2021 | 20988 | 0.430 |
Why?
|
Shock, Septic | 1 | 2018 | 769 | 0.400 |
Why?
|
Proportional Hazards Models | 6 | 2021 | 12447 | 0.390 |
Why?
|
Humans | 91 | 2024 | 760617 | 0.380 |
Why?
|
Waldenstrom Macroglobulinemia | 4 | 2022 | 1073 | 0.370 |
Why?
|
Electronic Health Records | 3 | 2023 | 4803 | 0.360 |
Why?
|
Pedigree | 1 | 2018 | 4539 | 0.350 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 2 | 2023 | 179 | 0.350 |
Why?
|
Computational Biology | 3 | 2020 | 3509 | 0.330 |
Why?
|
Head and Neck Neoplasms | 2 | 2020 | 2894 | 0.320 |
Why?
|
Receptor, erbB-2 | 7 | 2021 | 2553 | 0.300 |
Why?
|
Ovarian Neoplasms | 3 | 2021 | 4849 | 0.280 |
Why?
|
Endpoint Determination | 5 | 2017 | 590 | 0.280 |
Why?
|
Alleles | 1 | 2018 | 6861 | 0.280 |
Why?
|
Disease-Free Survival | 7 | 2021 | 6807 | 0.270 |
Why?
|
Paclitaxel | 4 | 2021 | 1730 | 0.270 |
Why?
|
Decision Making | 4 | 2023 | 3918 | 0.250 |
Why?
|
Sepsis | 1 | 2018 | 2585 | 0.240 |
Why?
|
Receptors, CXCR4 | 2 | 2019 | 727 | 0.230 |
Why?
|
Organophosphorus Compounds | 1 | 2024 | 206 | 0.210 |
Why?
|
Software | 2 | 2014 | 4431 | 0.210 |
Why?
|
Prospective Studies | 8 | 2022 | 54360 | 0.200 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2019 | 857 | 0.200 |
Why?
|
Neurofibromatosis 2 | 1 | 2024 | 383 | 0.180 |
Why?
|
Gene Expression Profiling | 3 | 2020 | 9417 | 0.180 |
Why?
|
Filgrastim | 1 | 2020 | 132 | 0.170 |
Why?
|
Camptothecin | 1 | 2023 | 591 | 0.170 |
Why?
|
Hematopoiesis | 3 | 2020 | 2049 | 0.170 |
Why?
|
Ketones | 1 | 2020 | 183 | 0.170 |
Why?
|
Paraproteinemias | 1 | 2022 | 248 | 0.160 |
Why?
|
Furans | 1 | 2020 | 202 | 0.160 |
Why?
|
DNA Mismatch Repair | 1 | 2022 | 428 | 0.160 |
Why?
|
Oxazoles | 2 | 2020 | 199 | 0.160 |
Why?
|
Uncertainty | 1 | 2024 | 752 | 0.160 |
Why?
|
Treatment Outcome | 13 | 2021 | 64568 | 0.160 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 202 | 0.150 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 380 | 0.150 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 2827 | 0.140 |
Why?
|
Sample Size | 2 | 2017 | 838 | 0.140 |
Why?
|
Anilides | 1 | 2019 | 411 | 0.130 |
Why?
|
Respiratory Tract Diseases | 1 | 2022 | 750 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2023 | 9277 | 0.130 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2020 | 617 | 0.130 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 997 | 0.130 |
Why?
|
Models, Genetic | 2 | 2018 | 3431 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 951 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2020 | 583 | 0.130 |
Why?
|
Female | 33 | 2024 | 392148 | 0.130 |
Why?
|
Nitroimidazoles | 1 | 2016 | 117 | 0.130 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2022 | 5672 | 0.130 |
Why?
|
Patient Care | 1 | 2021 | 621 | 0.120 |
Why?
|
Voltage-Sensitive Dye Imaging | 1 | 2014 | 29 | 0.120 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 1008 | 0.120 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2014 | 119 | 0.120 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1182 | 0.120 |
Why?
|
Cyclophosphamide | 1 | 2020 | 2218 | 0.110 |
Why?
|
Data Collection | 1 | 2023 | 3315 | 0.110 |
Why?
|
Doxorubicin | 1 | 2020 | 2224 | 0.110 |
Why?
|
BRCA2 Protein | 1 | 2018 | 797 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1086 | 0.110 |
Why?
|
Mutation | 6 | 2020 | 30016 | 0.100 |
Why?
|
Salvage Therapy | 1 | 2019 | 1263 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1084 | 0.100 |
Why?
|
Embryo, Mammalian | 2 | 2016 | 1670 | 0.100 |
Why?
|
Likelihood Functions | 1 | 2015 | 991 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2021 | 1156 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 3027 | 0.100 |
Why?
|
Genes, Neoplasm | 1 | 2014 | 370 | 0.100 |
Why?
|
BRCA1 Protein | 1 | 2018 | 1149 | 0.100 |
Why?
|
Reproducibility of Results | 5 | 2019 | 20074 | 0.090 |
Why?
|
Molecular Sequence Annotation | 1 | 2014 | 520 | 0.090 |
Why?
|
Models, Biological | 2 | 2020 | 9461 | 0.090 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 933 | 0.090 |
Why?
|
Survival Rate | 4 | 2020 | 12719 | 0.090 |
Why?
|
Pyridines | 2 | 2020 | 2874 | 0.090 |
Why?
|
Transplantation, Autologous | 3 | 2022 | 2112 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2021 | 3150 | 0.090 |
Why?
|
Markov Chains | 1 | 2014 | 965 | 0.090 |
Why?
|
Particulate Matter | 1 | 2022 | 2602 | 0.090 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4533 | 0.080 |
Why?
|
Prognosis | 7 | 2020 | 29600 | 0.080 |
Why?
|
Epidemiologic Methods | 1 | 2014 | 1335 | 0.080 |
Why?
|
Risk | 4 | 2022 | 9604 | 0.080 |
Why?
|
Drug Discovery | 1 | 2017 | 1051 | 0.080 |
Why?
|
Patient Participation | 1 | 2018 | 1443 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2014 | 3777 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1998 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4237 | 0.080 |
Why?
|
Life Expectancy | 1 | 2015 | 1239 | 0.080 |
Why?
|
Point Mutation | 1 | 2014 | 1595 | 0.080 |
Why?
|
Monte Carlo Method | 1 | 2014 | 1257 | 0.080 |
Why?
|
Disease Progression | 5 | 2024 | 13495 | 0.070 |
Why?
|
Receptors, Estrogen | 3 | 2020 | 2208 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3634 | 0.070 |
Why?
|
Aged | 17 | 2022 | 169042 | 0.070 |
Why?
|
Papillomavirus Infections | 1 | 2019 | 1611 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2019 | 3607 | 0.070 |
Why?
|
Asymptomatic Diseases | 2 | 2021 | 587 | 0.070 |
Why?
|
Cell Lineage | 1 | 2016 | 2554 | 0.070 |
Why?
|
Male | 17 | 2024 | 360358 | 0.070 |
Why?
|
Drug Administration Schedule | 3 | 2020 | 4845 | 0.070 |
Why?
|
Genomics | 2 | 2020 | 5822 | 0.070 |
Why?
|
Environmental Exposure | 1 | 2022 | 4483 | 0.070 |
Why?
|
Middle Aged | 17 | 2024 | 220584 | 0.070 |
Why?
|
Genotype | 2 | 2018 | 12978 | 0.070 |
Why?
|
DNA Copy Number Variations | 1 | 2015 | 2020 | 0.070 |
Why?
|
Databases, Factual | 1 | 2021 | 7960 | 0.060 |
Why?
|
Immunoglobulin M | 2 | 2022 | 1526 | 0.060 |
Why?
|
Receptors, Progesterone | 2 | 2020 | 1129 | 0.060 |
Why?
|
Tuberculosis | 1 | 2018 | 2015 | 0.060 |
Why?
|
Cross-Over Studies | 2 | 2022 | 2079 | 0.060 |
Why?
|
Single-Cell Analysis | 1 | 2016 | 2447 | 0.060 |
Why?
|
Recurrence | 2 | 2019 | 8426 | 0.060 |
Why?
|
Palliative Care | 1 | 2020 | 3592 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5304 | 0.060 |
Why?
|
Adult | 15 | 2024 | 220969 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2014 | 2734 | 0.060 |
Why?
|
Glioma | 1 | 2019 | 3453 | 0.060 |
Why?
|
Hearing Disorders | 1 | 2024 | 126 | 0.060 |
Why?
|
Stochastic Processes | 2 | 2015 | 355 | 0.060 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8516 | 0.060 |
Why?
|
Neoplasm Metastasis | 1 | 2014 | 4910 | 0.050 |
Why?
|
Administration, Oral | 2 | 2024 | 4010 | 0.050 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2014 | 3608 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 14648 | 0.050 |
Why?
|
Quinazolines | 2 | 2020 | 1371 | 0.050 |
Why?
|
Time Factors | 2 | 2021 | 39913 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2020 | 58894 | 0.050 |
Why?
|
Hippocampus | 1 | 2014 | 3761 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3514 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 627 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4745 | 0.050 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 3794 | 0.050 |
Why?
|
Immunologic Tests | 1 | 2021 | 104 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8645 | 0.050 |
Why?
|
MicroRNAs | 1 | 2017 | 3805 | 0.050 |
Why?
|
Premedication | 1 | 2021 | 245 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2017 | 8542 | 0.050 |
Why?
|
Risk Factors | 4 | 2022 | 74115 | 0.040 |
Why?
|
Dexamethasone | 2 | 2018 | 1947 | 0.040 |
Why?
|
Artificial Intelligence | 1 | 2014 | 2574 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11116 | 0.040 |
Why?
|
Rifampin | 1 | 2021 | 339 | 0.040 |
Why?
|
Models, Immunological | 1 | 2021 | 512 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3527 | 0.040 |
Why?
|
Bone Marrow | 2 | 2019 | 2909 | 0.040 |
Why?
|
Neurilemmoma | 1 | 2024 | 524 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2017 | 2014 | 0.040 |
Why?
|
Benzylamines | 1 | 2019 | 246 | 0.040 |
Why?
|
Melanoma | 1 | 2017 | 5697 | 0.040 |
Why?
|
Heterocyclic Compounds | 1 | 2019 | 245 | 0.040 |
Why?
|
Tumor Burden | 1 | 2024 | 1892 | 0.040 |
Why?
|
beta 2-Microglobulin | 1 | 2019 | 328 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11106 | 0.040 |
Why?
|
Dioxygenases | 1 | 2020 | 344 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39063 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2020 | 2917 | 0.040 |
Why?
|
Creatinine | 1 | 2023 | 1896 | 0.040 |
Why?
|
Cell Differentiation | 1 | 2014 | 11514 | 0.040 |
Why?
|
Standard of Care | 1 | 2021 | 551 | 0.040 |
Why?
|
Young Adult | 5 | 2024 | 59179 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2021 | 858 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15498 | 0.030 |
Why?
|
Administration, Cutaneous | 1 | 2018 | 712 | 0.030 |
Why?
|
Purines | 1 | 2019 | 606 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2023 | 1985 | 0.030 |
Why?
|
Gene Dosage | 1 | 2020 | 1217 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2021 | 708 | 0.030 |
Why?
|
Heterozygote | 1 | 2022 | 2780 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2019 | 496 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2015 | 12661 | 0.030 |
Why?
|
Melphalan | 1 | 2017 | 420 | 0.030 |
Why?
|
Aminopyridines | 1 | 2019 | 573 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2214 | 0.030 |
Why?
|
Karyotyping | 1 | 2017 | 1171 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2022 | 2189 | 0.030 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2019 | 584 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2023 | 80566 | 0.030 |
Why?
|
Cisplatin | 1 | 2020 | 1650 | 0.030 |
Why?
|
Databases as Topic | 1 | 2016 | 473 | 0.030 |
Why?
|
Risk Assessment | 3 | 2021 | 23972 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2022 | 1852 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2015 | 473 | 0.030 |
Why?
|
Infection Control | 1 | 2021 | 982 | 0.030 |
Why?
|
Immune System | 1 | 2019 | 791 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1589 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2019 | 1117 | 0.030 |
Why?
|
Cohort Studies | 3 | 2022 | 41457 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 1827 | 0.030 |
Why?
|
Exosomes | 1 | 2017 | 424 | 0.030 |
Why?
|
Mice, SCID | 1 | 2017 | 2625 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2019 | 1350 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2019 | 1201 | 0.020 |
Why?
|
Breast | 1 | 2020 | 1963 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2017 | 14389 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15251 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2015 | 1437 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 4570 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2015 | 1113 | 0.020 |
Why?
|
Indoles | 1 | 2017 | 1830 | 0.020 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2015 | 937 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3599 | 0.020 |
Why?
|
Mice | 4 | 2017 | 81368 | 0.020 |
Why?
|
Air Pollution | 1 | 2022 | 2355 | 0.020 |
Why?
|
Air Pollutants | 1 | 2022 | 2893 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5672 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4512 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10754 | 0.020 |
Why?
|
Sulfonamides | 1 | 2017 | 1977 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2019 | 3567 | 0.020 |
Why?
|
Health Personnel | 1 | 2021 | 3333 | 0.020 |
Why?
|
Radiology | 1 | 2021 | 2113 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3868 | 0.020 |
Why?
|
Gene Expression | 1 | 2019 | 7568 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5239 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9313 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2014 | 2413 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6762 | 0.020 |
Why?
|
Prevalence | 1 | 2022 | 15689 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3680 | 0.010 |
Why?
|
Phenotype | 1 | 2022 | 16571 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6765 | 0.010 |
Why?
|
Animals | 4 | 2017 | 168201 | 0.010 |
Why?
|
Apoptosis | 1 | 2019 | 9476 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9586 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 13347 | 0.010 |
Why?
|
Child | 2 | 2024 | 80079 | 0.010 |
Why?
|
Hospitalization | 1 | 2022 | 10704 | 0.010 |
Why?
|
Adolescent | 2 | 2024 | 88234 | 0.010 |
Why?
|
United States | 2 | 2022 | 72272 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16967 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2017 | 22148 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 8998 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36402 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23416 | 0.010 |
Why?
|
Infant | 1 | 2015 | 36152 | 0.010 |
Why?
|
Child, Preschool | 1 | 2015 | 42188 | 0.010 |
Why?
|